Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers July 22, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - July 22, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/22/17 - "Kinase Inhibitors" in Patent Application Approval Process (USPTO 20170183343)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors CAPALDI, Carmelida; ARMANI, Elisabetta; JENNINGS, Andrew Steven Robert; HURLEY, Christopher, filed on December 22, 2016, was made available online on July 6, 2017, according to news reporting originating from Washington, D.C., by NewsRx c
7/22/17 - [I-bank focus]UOBKH lifts CSPC Pharma (01093) to HK$15.24 [ET Net News (China)]
UOB Kay Hian lifted its target price for CSPC. Pharmaceutical Group to HK $15.24 from HK $13.66, and maintained its "buy" rating. The research house held a conference call with CSPC's management.
7/22/17 - Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK [Arab Times (Kuwait)]
The pharma giants said Thursday afternoon that the FDA has accepted their application for erenumab, the furthest advanced CGRP therapy which is now navigating toward a May 17 PDUFA date. But payers will also be expected to consider Eli Lillys 2- day advantage, or a Phase III outcome for Amgen and Novartis that was quite similar to Alders for 70 mg
7/22/17 - Anti-Thrombin Activators Market: Upcoming Demands and Growth Analysis 2024
Transparency Market Research Report Added "Anti-thrombin Activators Market" to its database.Albany, NY 07/21/2017 Anti-thrombin activators are widely accepted due to their role in reducing thrombus formation. Anticoagulants, anti-platelet drugs, and thrombolytic drugs are some of the different types of anti-thrombin activators available, whic
7/22/17 - BrainStorm Wins $15.9M CIRM Grant for Phase III Trial of ALS Cell Therapy [Sport360]
BrainStorm Cell Therapeutics has won a $15.9 million grant from Californias regenerative medicine agency toward a Phase III trial of its amyotrophic lateral sclerosis cell therapy candidate NurOwn. NurOwn technology was developed in the laboratories of Dani Offen, Ph.D., and the late Eldad Melamed, M.D., at Tel Aviv University. BrainStorm said it i
7/22/17 - Cardiome's Partner SteadyMed Submits U.S. New Drug Application for TREVYENT for the Treatment of Pulmonary Arterial Hypertension
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Cardiome Pharma Corp. announced that partner SteadyMed Ltd submitted a New Drug Application to the U.S. Food and Drug Administration for TREVYENT . TREVYENT is a drug-device combination product that utilizes SteadyMed's PatchPump technology to deliver treprostinil, a.
7/22/17 - CHMP Recommends EU Approval for Roche's TECENTRIQ (Atezolizumab) in a Specific Type of Metastatic Lung and Two Types of Metastatic Bladder Cancer
Roche, a biotech company, issued the following news release:. Roche today announced that the EU Committee for Medicinal Products for Human Use has adopted a positive opinion for TECENTRIQ (R) as a monotherapy for the treatment of adults with locally advanced or metastatic non-small cell lung cancer after they have been previously treated with chemo
7/22/17 - Concert Pharmaceuticals, Lexington, Mass., Assigned Patent for Derivatives of Pyrazole-Substituted Amino-Heteroaryl Compounds
Concert Pharmaceuticals, Lexington, Massachusetts, has been assigned a patent developed by four co-inventors for "derivatives of pyrazole-substituted amino-heteroaryl compounds." The co-inventors are Bhaumik A. Pandya, Arlington, Massachusetts, Craig E. Masse, Cambridge, Massachusetts, Ian Robert Silverman, Arlington, Massachusetts, and Roger D. Tu
7/22/17 - Demand notices of Rs 74.65 crore issued to pharma firms: Government [Syrian Arab News Agency]
The government today said demand notices of Rs 74.65 crore have been issued to pharmaceuticals which have launched drugs without prior price approval from the National Pharmaceuticals Pricing Authority. During the monitoring of compliance of DPCO 2013 by drug makers, it was seen that the provisions related to `new drugs` had not been followed in so
7/22/17 - Dietary Supplements Market to Flourish US $252.1 Bn by 2025
North America is estimated to dominate the dietary supplements market through 2025. The market in Asia Pacific excluding Japan is projected to register the highest CAGR of 9.2% in terms of value between 2015 and 2025. Send an Enquiry@ Leading market playersKey players covered in the report are...
7/22/17 - Drug prices negotiated downward [China Daily: US Edition]
The prices of 36 expensive drugs- half of them for cancer treatment- are now covered by medical insurance, after the authorities negotiated substantial price reductions. The Ministry of Human Resources and Social Security negotiated with pharmaceutical manufacturers on 44 drugs and managed to cut prices of 36 of them to be acceptable for coverage b
7/22/17 - Egalet Announces Pricing of Public Offering of Common Stock and Warrants
By a News Reporter-Staff News Editor at Marketing Weekly News Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, announced the pricing of its underwritten public offering of 16,666,667 shares of its common stock and...
7/22/17 - Ema's Chmp Issues Positive Opinion for Avelumab for Treatment of Metastatic Merkel Cell Carcinoma
Pfizer, a pharmaceutical company, issued the following news release:. Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of avelumab* as
7/22/17 - FDA approves drug to reduce risk of HER2-positive breast cancer returning [Arab Finance (Egypt)]
The US Food and Drug Administration has approved neratinib as the first extended adjuvant therapy for early-stage, HER2-positive breast cancer. Neratinib is a kinase inhibitor that works by blocking several enzymes that promote cell growth. Richard Pazdur, director of FDAs Oncology Center of Excellence and acting director of the Office of Hematolog
7/22/17 - Global Outlook for Cold Plasma Market by Key Trends and Analysis 2026
Transparency Market Research Report Added "Cold Plasma Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016- 2026". Albany, NY 07/21/2017 Cold Plasma Market: Overview Cold plasma, popularly known as non-thermal plasma, is the new cutting edge concept that has wide applications in medical devices. The technology has
7/22/17 - GSK Receives FDA Approval for a New Self-Injectable Formulation of Benlysta (Belimumab) for Systemic Lupus Erythematosus
GlaxoSmithKline issued the following news release:. GSK announced today that the US Food and Drug Administration has approved a new subcutaneous formulation of Benlysta for the treatment of adult patients with active, autoantibody positive SLE who are receiving standard therapy. Systemic Lupus Erythematosus is the most common form of lupus, a ch
7/22/17 - Help Get Over-The-Counter Hearing Aids Act Passed
The growing influence of big-box stores such as Costco may make buying a hearing aid easier. By the way, Costco s optical and hearing aid departments both have licensed optometrists and hearing aid dispensers who are independent contractors and not Costco employees. The FDA prohibits manufacturers from marketing their products as hearing aids to
7/22/17 - Imaging Biomarkers Market - Positive Long-Term Growth Outlook 2023
Transparency Market Research Report Added "Imaging Biomarkers Market" to its database.Albany, NY 07/21/2017 An imaging biomarker is a biomarker that can be detected with the help of an imaging technology. Biomarkers are increasingly being applied as a diagnostic tool. According to the National Institutes of Health's National Cancer Institute,
7/22/17 - Ironwood slips as heartburn data underwhelm investors [Arab News (Saudi Arabia)]
A phase 2 b trial of Ironwood Pharmaceuticals IW-3718 has met its primary endpoint, teeing the heartburn candidate up to move into a pivotal trial and on to blockbuster sales. The divergence in interpretations of the data centers on whether the statistically-significant result against the primary endpoint is big enough to justify predictions of $2
7/22/17 - Janssen Receives Positive CHMP Opinion for SYMTUZA First Darunavir-Based Single-Tablet Regimen for Treatment of HIV
BEERSE, Belgium, July 21 Johnson and Johnson issued the following news release:. Janssen-Cilag International NV today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a Positive Opinion recommending marketing authorisation for SYMTUZA, a once-daily darunavir-based single tablet regimen.
7/22/17 - Kitov Pharma reports positive results from pre-clinical study of NT-219 in combo with Keytruda [Sport360]
Kitov Pharmaceuticals Holdings Ltd., an innovative biopharmaceutical company, announced results of a pre-clinical study demonstrating that NT-219, the lead drug candidate of its subsidiary TyrNovo Ltd., in combination with Keytruda, converted non-responding tumors to responders and blocked tumor progression in an immune-oncology preclinical model.
7/22/17 - LIDDS signs research agreement with major European pharma company [Tehran Times (Iran)]
-LIDDS has entered into a research agreement with a major pharmaceutical company which has an exclusive option right to leverage the NanoZolid technology for the development of an injectable, controlled-release formulation for cancer treatment. Under the terms of the agreement, LIDDS will conduct feasibility studies fully funded by the other party.
7/22/17 - MSDs Lantus biosimilar given conditional FDA approval [Sudan Tribune]
However, there is a hitch to the good news for MSD, it is dependent upon a patent infringement lawsuit brought against them by Sanofi. The tentative approval of Lusduna Nexvue is an important milestone, bringing us closer to offering this medicine to patients, said Sam Engel, Associate Vice President of Merck Clinical Research. For Sanofi, the appr
7/22/17 - NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in Extended Adjuvant Setting
McKesson issued the following news release:. Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.' s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Administration. "We are pleased to b
7/22/17 - PhRMA Industry Group Takes Defensive Stance on Drug Pricing in New Campaign [Sport360]
The pharmaceutical industry trade group PhRMA has launched a campaign called Lets Talk About Cost in which the lobbying group seeks to answer patients common questions about drug pricing. PhRMA announced the campaign in a post written by Robert Zirkelbach, Executive Vice President of Public Affairs at PhRMA, on The Catalyst blog. Zirkelbach points
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement